Capital Medical Center
Click Here to Subscribe!

E-Health Services

Daily Health News

  Latest News
  FDA Approvals
  FYI

Health Information

Newsletter Topics

Alzheimer's Disease
Anxiety
Arthritis
Blood Pressure
Breast Cancer
Cancer
Depression
Diabetes
Exercise / Fitness
Female Urological Disorders
Gastrointestinal Health
Healthy Diet
Heart Disease
Men's Health
Menopause
Neurology
Orthopedics
Pain Management
Parenting
Pediatrics
Pregnancy
Senior Caregiving
Seniors' Health
Sleep Disorders
Sports Medicine
Stroke
Weight Management
Women's Health
Women's Heart Health
Username: Password: Forgot password?
Remember me next time.
 FDA Approvals
Return to
Daily Health Main Page.
  Tweet it! Pin it!
  Emflaza Approved for Duchenne Muscular Dystrophy
 
First U.S. approval of corticosteroid to treat the disorder

 

THURSDAY, Feb. 9, 2017 (HealthDay News) --Emflaza (deflazacort) has been approved by the U.S. Food and Drug Administration to treat Duchenne muscular dystrophy in people five years and older, the agency said Thursday in a news release.

The corticosteroid is designed to reduce inflammation and suppress the immune system in people with DMD, the most common type of muscular dystrophy. The FDA said it's the first corticosteroid approved to treat DMD.

The genetic disorder leads to ongoing deterioration of the muscles. It's caused by a lack of dystrophin, a protein designed to keep muscle cells intact. Symptoms commonly begin between ages three and five, and boys are affected much more often than girls. The disorder affects about one of every 3,600 male infants worldwide, the agency said.

Most people with DMD require a wheelchair by their early teens. The majority die in their 20s and 30s, the FDA said, although life expectancy varies.

Emflaza was evaluated in a clinical study of 196 males aged five to 15, all with documented mutation of the dystrophin gene and onset of DMD symptoms before age five. After 12 weeks, people taking the drug showed muscle strength improvement, compared with those who took a placebo.

Side effects, similar to those caused by other corticosteroid medications, included facial puffiness, weight gain, increased appetite, upper respiratory tract infection, cough and increased need to urinate, the FDA said.

Emflaza is marketed by Marathon Pharmaceuticals, based in Northbrook, Ill.

More information

Learn more from the FDA.

 
 
 
 
   More  FDA Approvals
 
   •  New Parkinson's Drug Xadago Approved
  To help prevent 'off' episodes among users of levodopa/carbidopa
 
   •  Noctiva Approved for Frequent Urination at Night
  For adults who awaken to urinate at least twice nightly
 
   •  Xermelo Approved for Tumor-Related Diarrhea
  Drug will treat a condition called carcinoid syndrome diarrhea
 
   •  Siliq Approved for Plaque Psoriasis
  Injected drug is for use by patients who've failed other treatments
 
Health Content Provided By:
The health content is provided for informational and educational purposes. It is intended for the general population and may not reflect specific conditions or risk of an individual or segment of the population. Therefore, it is not intended to be a substitute for professional medical advice, consultation, treatment or diagnosis. Always seek the advice of your physician or other qualified health provider with questions. Never disregard professional medical advice or delay in seeking it because of information obtained through these services.
E-Home | E-Health Services | Sample News | Subscribe | Feedback | Contact Us | Privacy Policy | Terms & Conditions
 
© 2010 CAPITAL MEDICAL CENTER · 3900 CAPITAL MALL DRIVE SW · OLYMPIA, WA 98502 · 360-754-5858 · SITEMAP · PRIVACY POLICY · TERMS & CONDITIONS
 
ABOUT US SERVICES & TECHNOLOGY FOR PATIENTS & GUESTS FOR PHYSICIANS FOR EMPLOYEES COMMUNITY CAREERS